

**Results From ENHANCE Study Presented at American College of Cardiology Scientific Sessions  
and Published in On-Line Version of *The New England Journal of Medicine***

Data (change from study baseline)	Drug				P Value (Mean only) NS= not statistically significant
	Simvastatin (80 mg)		VYTORIN (10/80 mg ezetimibe/ simvastatin)		
	Mean	Median	Mean	Median	
<b>Baseline IMT</b>					
Baseline CA IMT (mm)	0.70	0.69	0.69	0.68	
<b>Primary Endpoint</b>					
Change in CA IMT at three CA sites (mm)	0.0058	0.0095	0.0111	0.0058	=0.29 (NS)
<b>Individual Components of Primary Endpoint</b>					
Far common carotid IMT (mm)	0.0024	0.0043	0.0019	0.0010	=0.93 (NS)
Internal carotid IMT (mm)	-0.0007	0.0057	0.0099	0.0066	=0.21 (NS)
Carotid bulb IMT (mm)	0.0062	0.0099	0.0144	0.0107	=0.37 (NS)
<b>Four Key Secondary Endpoints</b>					
Patients manifesting regression in CA IMT	44.4 percent (142/320)		45.3 percent (146/322)		=0.92 (NS)
Patients developing new CA plaques, pre-specified as lesions of 1.3 mm or larger in thickness	2.8 percent (9/320)		4.7 percent (15/322)		=0.20 (NS)
Change in the maximum CA IMT, pre-specified as the far wall maximum CA IMTs for the common carotids, carotid bulb, and internal carotids (mm)	0.0103	0.0103	0.0175	0.0160	=0.27 (NS)
Change in the CA IMT plus the common femoral artery IMT (mm)	0.0033		0.0182		=0.15 (NS)
<b>Lipid Parameters: LDL-C, Triglycerides, HDL-C; and C-reactive Protein</b>					
LDL-C	-39.1 percent (317.8± 66.1 to 192.7±60.3 mg/dL)		-55.6 percent (319.0± 65.0 to 141.3±52.6 mg/dL)		<0.01
Triglycerides		-23.2 percent (160 to 120 mg/dL)		- 29.8 percent (157 to 108 mg/dL)	<0.01 (median)
HDL-C	+7.8 percent (47.4±13.2 to 50.7±14.7 mg/dL)		+10.2 percent (46.7±11.3 to 50.9±12.8 mg/dL)		=0.05
C-reactive Protein		-23.5 percent (1.70 to 1.20 mg/dL)		-49.2 percent (1.70 to 0.90 mg/dL)	<0.01 (median)
<b>Pre-Specified Cardiovascular Events</b>					
Cardiovascular deaths	1/363		2/357		
Nonfatal heart attacks	2/363		3/357		
Nonfatal strokes	1/363		1/357		
Revascularization	5/363		6/357		
<b>Adverse Events</b>					
Incidence of consecutive elevations of serum transaminases (≥ 3x ULN)	2.2 percent (8/360)		2.8 percent (10/356)		
Incidence of elevated creatine phosphokinase (CPK) (≥ 10x ULN)	2.2 percent (8/360)		1.1 percent (4/356)		
Cases of elevated CPK associated with muscle symptoms	0.3 percent (1 case)		0.6 percent (2 cases)		